Lynozyfic (linvoseltamab-gcpt)

Bispecific antibody for multiple myeloma

SKU: lynozyfic-linvoseltamab Category: Multiple Myeloma Tags: bcma, bispecific, multiple-myeloma, oncology

Description

Lynozyfic (linvoseltamab-gcpt) is a BCMA x CD3 bispecific antibody used in the treatment of multiple myeloma.

There are no reviews yet.

Be the first to review “Lynozyfic (linvoseltamab-gcpt)”